The Obama administration may need to make still more changes to protect consumer privacy on the government's health insurance website.» Read More
As debate rages over costly drugs like Gilead's Solvadi, patients caution: Treatment is priceless.
Here are some apps recommendations from "Valley Girl" Jesse Draper that can help you manage your health.
Many people who previously spent lots of money for prescriptions will be helped by Obamacare, but some may be surprised at what they still owe.
The mounting scrutiny of prescription drug prices in the U.S. reached fever pitch with total spending last year rising 3.2 percent, to $329.2 billion.
U.S. pharmaceutical giant releases statement confirming that it would not be making a further multibillion-dollar offer for its U.K. rival.
Express Scripts' Steve Miller has embarked on a drug pricing crusade, with the goal of bringing down costs.
People are more stressed out at home than they are at work, new research shows, but that may be because they are trying to juggle so much.
New research from the Consumer Financial Protection Bureau concludes that medical bills are unfairly lowering credit scores.
AstraZeneca is battling to shore up shareholder support to resist Pfizer's £69.4bn takeover as the US giant makes another push to revive the deal. The FT reports.
A possible White House move to bail out insurance companies would be a slip toward government domination of health care, Athenahealth CEO Jonathan Bush says.
Nevada's health-care exchange is cutting ties with Xerox and will partner with the federal system for 2015, the Las Vegas Review Journal reported.
Instead of criticizing foreign deals, we should be talking about corporate-tax reform to bring business—and jobs—back to the US, says Jake Novak.
In an interview with CNBC, Dr. Mehmet Oz also talked about what he considers the most underrated path to healthy living.
Part of the VA's problem is about supply and demand, and it's the same problem facing the country's health-care system, says Dr. Schnipper
Mobile health can be part of a cure for rising insurance costs. Here are six preventative health apps that can help consumers and employers.
As AstraZeneca's shares slid following its rejection of Pfizer's new bid, the company's chairman said he was "reasonably confident" it was the right decision.
Activist investor William Ackman told Allergan's board that the CEO has a 'disabling' conflict of interest because a takeover means losing his job.
AstraZeneca shares fall 13 percent after it rejects a final bid from Pfizer, calling the offer inadequate and presenting significant risks.
Chinese police have charged several former GlaxoSmithKline employees as the British drug maker is accused of evading million in Chinese taxes.
It's new, it's undoubtedly deadly. But is MERS creating too much panic? That may be the case, says one expert.
Get the best of CNBC in your inbox